It has been full steam ahead since Vianautis moved to its new workspace at our Unity Campus development in South Cambridge. Not only has it just announced a strategic collaboration Agreement with Eli Lilly and Company to leverage its polyNaut® platform to develop novel products delivering genetic medicines, it has also welcomed new CEO Dr Adi Hoess, and Dr Ray Jupp as the new CSO. Congratulations to Francesca Crawford and the Vianautis team on this outstanding success. You can keep up-to-date with the news from this groundbreaking Unity Campus -based biotechnology company here: https://lnkd.in/ePsk4mUM #GeneticMedicines #nanomedicine #BioTech #Cambridge
Today we have announced a strategic collaboration with Eli Lilly and Company to develop novel genetic medicines using our polyNaut® platform: https://lnkd.in/eH7Qh53F This marks a significant step forward in leveraging our polyNaut® nanovesicle platform, designed to precisely target specific tissues and cell types, even in hard-to-reach areas such as the central nervous system. With its ability to efficiently deliver genetic cargoes, polyNaut® has the potential to transform genetic nanomedicine delivery and address significant unmet needs. #ViaNautis #polyNaut #Lilly #Biotech #Nanomedicine